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Positron Emission Tomography/Computed Tomography (FDG-
PET/CT) standardized uptake value (SUV) and total lesion 
glycolysis (TLG) with tumour characteristics and clinical 
response in a series of rectal cancer patients treated with 
neoadjuvant chemo-radiotherapy 
 
Material and Methods: Fifty-six patients were included in the 
present analysis. Pre-treatment PET maximum SUV (SUVmax), 
mean SUV and TLG of primary tumour were calculated for 
each patient. The total dose of pelvic radiotherapy was 45-
50.4 Gy, 1.8 Gy/fraction. Chemotherapy was delivered with 
capecitabina or 5-fluorouracil. Six to eight weeks after RT-
CT, 44 patients (78.6%) had anterior rectal resection and 12 
patients (21.4%) had abdominal pelvic resection (Miles).  
Tumor Regression Grade (TRG) (Mandard, 1994) was defined 
on surgical specimen. Complete regression (TRG1) was 
observed in 10/56 (17.9 %).The correlation between PET/CT 
results and histopathological data and tumour response was 
analyzed.  
 
Results: At the level of the primary tumour, SUVmax ranged 
from 4.17 to 54.06 (mean 22.46, median 18.89), SUV mean 
ranged from 6.22 to 32.64 (mean 13.42, median 11.09) and 
TLG ranged from 7.96 to3158.23 (mean 350.21, median 
183.55).SUVmax (p=0.05) and TLG (p=0.002) significantly 
correlated with T-stage. Median SUVmax was significantly 
higher (p = 0.05) for lesions with partial response (PR, 46/56, 
82.1%) than for lesions with complete response (CR, 34/54, 
17.9%). Median TLG was significantly higher (p=0.034) for 
lesions with partial response (PR, 45/54, 83.3%) than for 
lesions with complete response (CR, 9/54, 16.7%). 
SUVmean was not significantly correlated with T-stage 
(p=0.074). Median SUVmean was higher for lesions with 
partial response (PR, 45/54, 83.3%) than for lesions with 
complete response (CR, 9/54, 16.7%) but without statistical 
significance (p =0.18).  
 
Conclusion: Our data suggest that pre-treatment FDG-
PET/CT SUVmax and TLG are strongly associated with tumour 
primary tumour stage. Furthermore they correlate with 
prediction of tumour response after neoadjuvant treatment 
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Purpose or Objective: To evaluate pathological response and 
clinical outcomes in women with locally advanced cervical 
cancer treated with radiochemotherapy and surgery in a 
tertiary hospital. 
 
Material and Methods: In this retrospective analysis we have 
included 59 patients with cervical cancer (FIGO stages IB2-
IVA) who were treated between December 2004 and July 
2015 with concurrent chemoradiation therapy (CCRT) 
followed by surgery. The patients were treated with pelvic 
external beam radiotherapy at 46-50,4 Gy, 1,8-2 Gy/day. 
Based on CT or PET CT if aortic nodes were demonstrated, 
extended external beam radiotherapy was performed. We 
boosted nodes or parametria if they were affected (60-68 Gy, 
2 Gy/day). After four weeks of treatment, patients received 
brachytherapy from 15 to 26 Gy in 3-6 fractions with 2D 
planification or 3D planification (n=28), with a total tumour 
dose between 85 and 90 Gy. Concurrent chemotherapy with 
weekly platin and in some cases oral fluoropirimidine was 
administrated. Overall treatment time did not exceed 8 
weeks. All patients completed surgery between 4-15 weeks 
after CCRT. 
 
Results: The median age was 52 years (range 30 and 77). 
Squamous cell carinoma was the most common subtype 
(81%). All patients received hysterectomy. 7 patients (12%) 
underwent lymphadenectomy. In global, 32 patients (54%) 
had a complete response, 20 (34%) a partial response and 7 
(12 %) patients had residual microscopic disease in the 
pathologic analysis. With a median follow up of 53 months 
(range from 2 to 128 months) overall survival was 85% and 
disease free survival 81% 
 
Conclusion: Our results show that CCRT followed by surgery 
gets excellents outcomes with acceptable toxicity and may 
reduce local recurrences. Besides it enables assessment of 
the pathological response. 
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Purpose or Objective: To quantify the magnitude of clinician 
uncertainty in GTV delineation for patients with recurrent 
gynaecological cancers. 
 
Material and Methods: GTV delineation uncertainty was 
retrospectively investigated in patients previously treated in 
our institution for centrally recurrent gynaecological cancer. 
In order to record clinician delineation uncertainty, clinicians 
were asked to draw 3 outlines per GTV; an inner GTV (GTV_I) 
corresponding to the innermost boundary the GTV is likely to 
have, an outer GTV (GTV_O)corresponding to the outmost 
boundary the GTV is likely to have and a clinical GTV (GTV_C) 
outlined in accordance with local treatment protocols. For 
GTV_C, each observer submitted a confidence score from 1 
to 5, with 1 being no confidence in drawn and 5 complete 
confidence. For each patient, the 3 GTV’s were delineated 
on a co-registered CT-MR, using a local rigid soft tissue 
registration, as well as on MR images only in order to identify 
how the co-registered CT information affects the decision 
process. Paired T Tests (p) were used to test for significance 
and Pearson correlation coefficient (r) for correlations. 
 
Results: To date, 18 recurrences from 17 patients were 
investigated by a single observer. For all 17 MR only contours 
and for 15 out of the 17 CT-MR contours, the GTV_O and 
GTV_C were identical. GTV_C ranged from 6.3 to 192.9cm3 
for CT-MR contours and from 5.5 to 180.1cm3 for the MR only 
contours, with a mean ± standard deviation of 53.3±44.7cm3 
and 39.3±40.4cm3 respectively. The reduction in GTV_I 
relative to GTV_C was 19.6±12.4cm3 (p<0.01) for CT-MR 
contours and 13.3±9.8cm3 (p<0.01) for MR only contours. For 
GTV_C, MR only contours were consistently smaller than CT-
MR contours by 14.0±11.4cm3 (p<0.01). For GTV_I, MR only 
contours were smaller for 13 out of the 17 cases, with 
differences of 7.9±7.7cm3 (p<0.01). The 3D difference in the 
centre of mass (COM) between GTV_O and GTV_C was 2±2mm 
for the CT-MR contours and 2±1mm for the MR only contours. 
Scoring of GTV_C was significantly lower (p<0.01) for CT-MR 
contours relative to MR only contours, with scores of 2.8±0.6 
and 3.6±0.7 respectively. 
 
Conclusion: Uncertainty exists in defining the boundary of 
the GTV for this patient cohort resulting in uncertainty in 
